Deducing the Bioactive Face of Hydantoin Anticonvulsant Drugs Using NMR Spectroscopy

Kathryn E Tiedje, Donald F Weaver

ABSTRACT: Background: The general purpose of this study was to deduce the geometry of the bioactive face (pharmacophore) for the hydantoin class of anticonvulsants. Methods: Six hydantoin analogs, selected as probes of hydantoin structure, were synthesized. Nuclear magnetic resonance spectroscopy and molecular modelling calculations were used to determine the geometric relationship between the aromatic group and the amide group in the hydantoin pharmacophore. Results: In accord with both theoretical and experimental results, the biologically inactive hydantoin analogs containing a benzyl substituent existed in a folded conformation with the benzene flopped over the hydantoin ring. Conversely the biologically active hydantoins had a phenyl ring extended away from the hydantoin ring. Conclusions: The bioactive face for hydantoins consists of a N(H)-C(=O)-X-phenyl molecular fragment, where X is a carbon or nitrogen atom and where the distance between the center of the amide bond and the centroid of the phenyl ring is 4.3 Å.

RÉSUMÉ: Utilisation de la spectroscopie par résonance magnétique nucléaire pour déduire la face bioactive des médicaments anticonvulsivants de la classe de l’hydantoïne. Contexte : Le but de cette étude était de déduire quelle est la géométrie de la face bioactive (pharmacophore) des anticonvulsivants de la classe de l’hydantoïne. Méthodes : Six analogues de l’hydantoïne choisis comme sondes pour examiner la structure de l’hydantoïne ont été synthétisés. La spectroscopie par résonance magnétique nucléaire (RMN) et des calculs par modélisation moléculaire ont été utilisés pour déterminer la relation géométrique entre le groupe aromatique et le groupe amide dans le pharmacophore de l’hydantoïne. Résultats : Les analogues de l’hydantoïne qui contiennent un substituant benzyle sont inactifs au point de vue biologique et possèdent une conformation repliée, le benzène étant rabattu sur l’anneau hydantoïne, ce qui concorde avec les données théoriques et expérimentales. À l’opposé, les analogues bioactifs de l’hydantoïne ont un anneau phényle qui s’écarte de l’anneau hydantoïne. Conclusions : La face bioactive des analogues de l’hydantoïne consiste en un fragment moléculaire N(H)-C(=O)-X-phényle où le X est un atome de carbone ou d’azote et où la distance entre le centre du pont amide et le centroïde de l’anneau phényle est de 4,3 Å.


All drugs are molecules, but not all molecules are drugs. Specific dimensions and physical properties are required for a molecule to become a successful drug. Anticonvulsant drugs are molecules whose geometric dimensions permit an ability to interact with a receptor and to elicit a desired seizure suppressing response. The entire anticonvulsant molecule is not required for this bioactivity; the fragment of the drug molecule that actually interfaces and docks with the receptor is termed the “bioactive face” (or pharmacophore). Thus, a bioactive face possesses one or more clusters of atoms positioned in three-dimensional space on a structural framework, holding them in a defined geometrical array that enables the molecule to bind specifically to a targeted biological macromolecular receptor. In modern drug design, an understanding of the geometry of the bioactive face is crucial for

From the Departments of Medicine (DFW) and Chemistry (KET, DFW), School of Biomedical Engineering (DFW), Dalhousie University, Halifax, Nova Scotia, Canada.

Reprint requests to: Donald F. Weaver, Departments of Medicine and Chemistry, Chemistry Building, Dalhousie University, Halifax, Nova Scotia, B3H 4J3, Canada.
drug discovery and design. Although therapeutic molecules such as phenytoin (5,5-diphenylhydantoin) have long been the mainstay of anticonvulsant therapy, the hydantoin bioactive face remains incompletely elucidated. This is a potential stumbling block to the rational development of Na+ channel-active agents for seizure suppression.2

Previous work from our laboratory and others has clearly shown that the bioactive face of hydantoin contains of an amide group (R'-N(=H)-C(=O)-R") and a lipophilic (preferably aromatic [e.g. phenyl]) group.3,4 Although this work has qualitatively identified the molecular building blocks of the bioactive face, it has not quantitatively deduced the precise geometric relationship between the lipophilic group and the amide group.

The main purpose of this study was to synthesize selected hydantoin analogues as structural probes and then to use nuclear magnetic resonance (NMR) spectroscopy and molecular imaging/modelling calculations to determine the precise geometric relationship between the lipophilic group and the amide group; this will then be correlated with bioactivity. This study will afford an improved understanding of the geometry of the bioactive face of phenytoin and the overall hydantoin class.

METHODS AND MATERIALS

Selection and Synthesis of Hydantoin Analogues

The phenyl ring was selected as a structural probe for the lipophilic group. Specific hydantoins were chosen to evaluate the influence of aromatic/amide geometry on anticonvulsant bioactivity (shown in Figure 1). To explore molecular diversity space, these compounds all contain an aromatic group at either the N3 or C5 position.

Appendix A presents the syntheses of compounds 1, 2, 3, 4, 5 and 6, which were prepared according to similar literature preparations.5-11 1H and 13C nuclear magnetic resonance spectra were recorded using a Bruker AVANCE 500MHz spectrometer. Chemical shifts (δ) are reported as parts per million downfield from the tetramethylsilane (TMS) and are calibrated using the solvent peaks or when possible, the TMS peak present some of the deuterated solvents. Coupling constants (J) are reported in Hz.

Biological Testing of Hydantoin Analogues

The six hydantoin analogues were each administered to five adult male Sprague Dawley rats at 20 mg/kg intraperitoneally; 15 minutes later pilocarpine (300 mg/kg) was administered intraperitoneally.12-14 The number of rats showing generalized convulsions was determined. These results are in agreement with biological activities as determined in a maximal electroshock assay (obtained from different laboratories using varying techniques) taken from literature sources.15

Nuclear Magnetic Resonance Spectroscopy Structural Analyses of Hydantoin Analogues

Molecular shape analysis (i.e. conformational analysis) of the six hydantoins was performed using one dimensional nuclear-Overhauser effect (nOe) spectroscopy (1D-NOESY) experiments. The nOe is a through-space effect and can be used to determine if a specific 1H proton is positioned near another 1H proton. This NMR experiment can be a particularly powerful tool for determining the spatial relationship of protons in a molecule. All NMR experiments were performed on a Bruker AVANCE 500 MHz spectrometer, in deuterated DMSO-d6 at 25ºC. The N1 and N3 protons at 7.92 ppm and 10.43 ppm for compound 1 and the deuterated solvents. Coupling constants (J) are reported in Hz.

Molecular Modelling Calculations of Hydantoin Analogues

Theoretical molecular modelling calculations were used to determine the optimal geometry of the hydantoin analogues. This was achieved by using a “mechanics” method that permits the geometry of a hydantoin molecule to be expressed as a function of energy; by minimizing this energy function, one can ascertain the optimal geometry of the hydantoin molecule. In this study, molecular mechanics was the mechanics method employed. Molecular mechanics refers to a heavily parameterized calculational method that leads to accurate geometries and accurate relative energies for different conformations of molecules. Molecular mechanics concept-ualises a molecule as a collection of particles held together by elastic or harmonic forces, which can be defined individually in terms of potential energy functions. The sum of these various potential energy equations comprises a multidimensional energy function termed the force field, which describes the restoring forces acting on a molecule when the minimal potential energy is perturbed. Thus, molecular mechanics uses an empirically derived set of simple classical mechanical equations, and is in principle well suited to provide accurate a priori structures and energies for varying conformations of hydantoin analogues.

The energy minimization molecular modelling calculations were performed using the MM2 force field implemented in

---

**Figure 1:** General structure of the hydantoin derivatives synthesized, where the Rn group are as follows: Bn = benzyl (-CH2C6H5); Ph = phenyl (-C6H5); H = hydrogen.
Table 1: The calculated mean distances and standard deviations between the centre of the amide bond and the centroid of the aromatic ring and the anticonvulsant activities, where the values indicate the number of animals tested compared to the number of animals that exhibited seizure protection.

<table>
<thead>
<tr>
<th>#</th>
<th>Compound Name</th>
<th>Calculated Distance (Å)</th>
<th>Biological Testing</th>
<th>Animals Tested</th>
<th>Animals Protected</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>(S)-5-benzylhydantoin</td>
<td>N1 3.8 ± 0.1, N4 4.0 ± 0.1</td>
<td></td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>(S)-5-phenylhydantoin</td>
<td>N1 4.2 ± 0.1, N4 4.3 ± 0.1</td>
<td></td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>5,5-diphenylhydantoin</td>
<td>N1 4.2 ± 0.1/4.1 ± 0.1, N4 4.3 ± 0.1/4.3 ± 0.1</td>
<td></td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>4</td>
<td>3-benzylhydantoin</td>
<td>N1 5.5 ± 0.1, N4 3.9 ± 0.1</td>
<td></td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>3-phenylhydantoin</td>
<td>N1 4.4 ± 0.1, N4 3.5 ± 0.1</td>
<td></td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>(S)-3,5-diphenylhydantoin</td>
<td>N1 4.7 ± 0.1/4.2 ± 0.1, N4 3.5 ± 0.1/4.2 ± 0.1</td>
<td></td>
<td>5</td>
<td>0</td>
</tr>
</tbody>
</table>

Chem 3D Ultra 8.016 where an extended geometry was used as the starting conformation for each molecule.

Results

Compounds 1 and 2 are both substituted at the C5 position but show varying ability to prevent seizure activity with only a one carbon chain length difference at the C5 position (benzyl vs. phenyl); compounds 4 and 5 are both substituted at the C3 position but show varying ability to prevent seizure activity with only a one carbon chain length difference at the C3 position (benzyl vs. phenyl).

The computationally optimized geometries of (S)-5-benzylhydantoin and (S)-5-phenylhydantoin show clear differences in the calculated distance between the N3 amide bond and the aromatic ring (Table 1). The 1D-NOESY studies of (S)-5-benzylhydantoin (1) showed a no nOe effect between the protons of the N3 amide bond (7.92 ppm/10.43 ppm) and the protons of the aromatic ring (7.18 ppm). The no nOe effects observed in (S)-5-phenylhydantoin (2) between the N1 amide bond proton (6.80 ppm) and the aromatic protons (7.34 ppm-7.40 ppm) was weaker in comparison (no nOe enhancement was seen between the N3 amide bond proton (12.82 ppm) and the aromatic protons (7.34 ppm-7.40 ppm)) (see Figure 2). (The 1D-NOESY spectra are available at http://chemistry.dal.ca/Faculty/Professors/Weaver%2C_Don.php).

Discussion

The correlation between structure and anticonvulsant activity is apparent from the biological results in the Table. The 1D-NOSEY data provide important conformational information that supports the molecular modelling results. Observation of the 1D-NOESY results for (S)-5-benzylhydantoin shows a through space interaction between the N1 proton at 7.92 ppm and the protons of the aromatic ring at 7.18-7.29 ppm. The nOe data help to support the hypothesis of a folded conformation for the (S)-5-benzylhydantoin (1), with the benzene ring being flopped over the hydantoin ring. This confirms a spatial relationship between the N1 amide and the aromatic moiety of the benzyl group. The nOe for (S)-5-phenylhydantoin (2) support the hypothesis that the aromatic ring is in an extended position relative to the hydantoin ring, and is not in a folded conformation as in the 5-benzyl analogue. Accordingly the 1D-NOSEY results show limited or no nOe enhancement for (S)-5-phenylhydantoin (2) between the N1/N3 amide bond protons (6.80 ppm/12.82 ppm) and the aromatic protons (7.34 ppm-7.40 ppm), which is compatible with computational and biological results.

Computational studies support these experimental results. For (S)-5-benzylhydantoin (1), an intramolecular interaction between the aromatic ring and the hydrogen of the N1 amide bond creates a folded geometry which is controlled by a non-bonded interaction between the pi-electrons of the aromatic ring and the dipole of the amide bond.17,19 The (S)-5-phenylhydantoin (2) is an active compound and assumes a conformation with the aromatic ring extended away from the hydantoin ring and the N3 amide bond. For the C5 substituted bioactive hydantoin analogues, the N3-C4(=O7) amide-to-phenyl distance is 4.3 ± 0.1 Å. 3-Phenylhydantoin (5) is a biologically active compound with a calculated amide bond-to-phenyl ring distance of 4.4 ± 0.1 Å. This distance is similar to the bioactive C5 substituted compounds. The inactivity of 3,5-diphenylhydantoin (6)
probably arises from the steric bulk of having a phenyl ring attached to the amide moiety.

In conclusion, the bioactive face for hydantoins consists of a R'-N(H)-C(=O)-X-phenyl molecular fragment, where X is a carbon or nitrogen atom and where the distance between the centre of the amide bond and the centroid of the phenyl ring is 4.3 Å. For compounds 2 and 3, the bioactive face is the N3-C4(=O7)-C5-R4; for compound 5 an equivalent bioactive face is N1-C2(=O6)-N3-R2. This extended geometry of the amide bond/ aromatic ring pharmacophore aids in binding to the fast-inactivated state of the neuronal sodium channel, thereby inhibiting seizure activity.

ACKNOWLEDGEMENTS

KET acknowledges salary support from the Nova Scotia Health Research Foundation and Epilepsy Canada. DFW acknowledges salary support from a Canada Research Chair, Tier 1, in Neuroscience. Molecular modelling software was acquired with the support of a grant from the Dalhousie Medical Research Foundation. The authors have no conflicts of interest to declare.

REFERENCES

50mL of water and 50mL of concentrated HCl (5 mL). When the solution had cooled the product crystallized. It was then collected by filtration and then recrystallized using an ethanol and water (95:5) mixture. (Crystalline product (7.4 g, 84%); mp=155-157°C (lit. mp = 154-155°C [8]); 1H NMR (CD3OD): 4.21 (s, 2H), 7.31-7.45 (m, 5H); 13C NMR (CD3OD): 58.8, 126.8, 127.4, 128.2, 129.3, 158.7, 174.4; HRMS: C9H18N2O2 calculated 176.0586 amu, found 176.0583 amu.)

(S)-3,5-Diphenylhydantoin (6)

A solution of L-phenylglycine (7.5 g, 0.05 mol) was dissolved in water (20 mL) containing potassium hydroxide (3.0 g, 0.05 mol), after the solution was stirred for 10 min, phenylisocyanate (6.0 g, 0.05 mol) was added and the mixture was warmed to 65 °C for 5 h. The solution was then cooled and left to sit for 2 h at which time the precipitated diphenylurea was filtered off and the filtrate was acidified with concentrated HCl (5 mL) to precipitate the hydantoic acid. The hydantoic acid obtained was then cyclized by heating it at reflux for 1 h in 50 mL of water and 50 mL of concentrated HCl. When the solution was cooled the product crystallized and was collected by filtration. It was then recrystallized using an ethanol and water (95:5) mixture. (Crystalline product (9.84 g, 78%); mp=157-159°C (lit. mp=158-160°C [8]); 1H NMR (CD3OD): 4.14 (s, 1H), 7.39-7.48 (m, 10H); 13C NMR (CD3OD): 57.4, 126.6, 127.4, 127.6, 127.9, 128.3, 128.4, 129.1, 129.7, 159.3, 173.2; HRMS: C15H12N2O2 calculated 252.0899 amu, found 252.0889 amu.)